BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 3625258)

  • 21. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities.
    Yeh SD; Larson SM; Burch L; Kushner BH; Laquaglia M; Finn R; Cheung NK
    J Nucl Med; 1991 May; 32(5):769-76. PubMed ID: 1902508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute pain relief after Mantram meditation in children with neuroblastoma undergoing anti-GD2 monoclonal antibody therapy.
    Ahmed M; Modak S; Sequeira S
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):152-5. PubMed ID: 24065045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
    Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
    Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
    Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
    Murray JL; Cunningham JE; Brewer H; Mujoo K; Zukiwski AA; Podoloff DA; Kasi LP; Bhadkamkar V; Fritsche HA; Benjamin RS
    J Clin Oncol; 1994 Jan; 12(1):184-93. PubMed ID: 8270976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.
    Cheung NK; Landmeier B; Neely J; Nelson AD; Abramowsky C; Ellery S; Adams RB; Miraldi F
    J Natl Cancer Inst; 1986 Sep; 77(3):739-45. PubMed ID: 3091900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
    Yu AL; Uttenreuther-Fischer MM; Huang CS; Tsui CC; Gillies SD; Reisfeld RA; Kung FH
    J Clin Oncol; 1998 Jun; 16(6):2169-80. PubMed ID: 9626218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.
    Vadhan-Raj S; Cordon-Cardo C; Carswell E; Mintzer D; Dantis L; Duteau C; Templeton MA; Oettgen HF; Old LJ; Houghton AN
    J Clin Oncol; 1988 Oct; 6(10):1636-48. PubMed ID: 3171629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro.
    Hank JA; Surfus J; Gan J; Chew TL; Hong R; Tans K; Reisfeld R; Seeger RC; Reynolds CP; Bauer M
    J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):29-37. PubMed ID: 8110728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
    Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
    Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma.
    Bhandari S; Cheung NK; Kushner BH; Kramer K; Modak S; Larson SM; Yeh S; Heller G; Sklar CA
    Pediatr Blood Cancer; 2010 Jul; 55(1):76-80. PubMed ID: 20213847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8.
    Bergman I; Arbit E; Rosenblum M; Larson SM; Heller G; Cheung NK
    J Neurooncol; 1993 Mar; 15(3):235-42. PubMed ID: 8360709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.
    Tsao CY; Sabbatino F; Cheung NK; Hsu JC; Villani V; Wang X; Ferrone S
    Oncoimmunology; 2015 Aug; 4(8):e1023975. PubMed ID: 26405581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
    Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
    JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.
    Saleh MN; Khazaeli MB; Wheeler RH; Dropcho E; Liu T; Urist M; Miller DM; Lawson S; Dixon P; Russell CH
    Cancer Res; 1992 Aug; 52(16):4342-7. PubMed ID: 1643631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study.
    Cheung NK; Kushner BH; Yeh SJ; Larson SM
    Prog Clin Biol Res; 1994; 385():319-28. PubMed ID: 7972227
    [No Abstract]   [Full Text] [Related]  

  • 37. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
    Munn DH; Cheung NK
    Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors.
    Ahmed M; Goldgur Y; Hu J; Guo HF; Cheung NK
    PLoS One; 2013; 8(5):e63359. PubMed ID: 23696816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
    Ye JN; Cheung NK
    Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
    Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.